netFormulary NHS
North East and North Cumbria
ICS Formulary
 Search
 Recent Updates - Updated items

All Formulary Amendments

  Records 61 to 90 of 96

New Newer Older Oldest

Details
UPD isDraft Changed from N to Y
26/04/2022 12:09:28
(DavidS )
UPD FurtherInformation Changed from
26/04/2022 12:09:28
(DavidS )
UPD Pembrolizumab NICE TA766. APC - April 2022
26/04/2022 12:09:28
(DavidS )
UPD sitematrix Changed from 0 to
26/04/2022 11:35:45
(DavidS )
UPD isCDF Changed from Y to N
26/04/2022 11:35:45
(DavidS )
UPD isCyto Changed from 0 to 1
26/04/2022 11:35:45
(DavidS )
UPD Pembrolizumab updated
26/04/2022 11:35:45
(DavidS )
UPD Pembrolizumab Published from Draft Mode
03/02/2022 12:34:13
(DavidS )
LDL Link Added : NICE TA737: Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer : https://www.nice.org.uk/guidance/ta737
03/02/2022 11:03:41
(DavidS )
UPD sitematrix Changed from 0 to
03/02/2022 11:03:20
(DavidS )
UPD isDraft Changed from N to Y
03/02/2022 11:03:20
(DavidS )
UPD FurtherInformation Changed from
03/02/2022 11:03:20
(DavidS )
UPD Pembrolizumab NICE TA737
03/02/2022 11:03:20
(DavidS )
LDL Link Added : NICE TA709: Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency : https://www.nice.org.uk/guidance/ta709
21/09/2021 11:03:26
(DavidS )
UPD sitematrix Changed from 0 to
21/09/2021 11:02:57
(DavidS )
UPD FurtherInformation Changed from
21/09/2021 11:02:57
(DavidS )
UPD Pembrolizumab NICE TA709
21/09/2021 11:02:57
(DavidS )
LUP Section link 19508 Updated: 08.01.05 : NICE TA692: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy : https://www.nice.org.uk/guidance/ta692...
21/09/2021 10:35:39
(DavidS )
LDL Link Added : :
21/09/2021 10:35:07
(DavidS )
UPD sitematrix Changed from 0 to
21/09/2021 10:34:54
(DavidS )
UPD FurtherInformation Changed from
  • Approved for the treatment of advanced melanoma after disease progression with ipilimumab in accordance with NICE.  
21/09/2021 10:34:54
(DavidS )
UPD Pembrolizumab NICE TA692
21/09/2021 10:34:54
(DavidS )
UPD Published from Draft Mode
20/05/2021 13:45:07
(LoweryM )
UPD Pembrolizumab updated
20/05/2021 13:42:09
(LoweryM )
UPD Pembrolizumab NICE TA683
19/05/2021 16:43:02
(DavidS )
LDL Link Added : NICE TA661: Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma : https://www.nice.org.uk/guidance/ta661
26/02/2021 11:15:21
(DavidS )
UPD Pembrolizumab NICE TA661
26/02/2021 11:14:05
(DavidS )
LDL Link Added : NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer : https://www.nice.org.uk/guidance/ta531
24/01/2019 14:31:27
(DavidS )
UPD Pembrolizumab NICE TA531
24/01/2019 14:31:05
(DavidS )
LDL Link Added : NICE TA357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab : https://www.nice.org.uk/guidance/ta357
01/02/2017 14:46:41
(DavidS )

 

 
netFormulary